Interleukin-17 as a potential therapeutic target for chronic pain

Chronic pain remains to be a clinical challenge and is recognized as a major health problem with varying impacts on quality of life. Currently, the first-line therapy for chronic pain is opioids, which are often accompanied by unwanted psychoactive side effects. Thus, new and effective treatments fo...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 999407
Main Authors Jiang, Xiaojuan, Zhou, Ruihao, Zhang, Yujun, Zhu, Tao, Li, Qian, Zhang, Weiyi
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 29.09.2022
Subjects
cancer
Immunology
inflammatory cytokines
inflammatory pain
interleukin-17
neuroinflammation
neuropathic pain
Online AccessGet full text

Cover

More Information
Summary:Chronic pain remains to be a clinical challenge and is recognized as a major health problem with varying impacts on quality of life. Currently, the first-line therapy for chronic pain is opioids, which are often accompanied by unwanted psychoactive side effects. Thus, new and effective treatments for chronic pain are urgently needed and eagerly pursued. Inflammatory cytokines, especially interleukin-17 (IL-17), are reportedly potential therapeutic targets owing to their pivotal role in chronic pain from the neuroinflammation perspective. Recently, substantial evidence confirmed that IL-17 and IL-17 receptors (IL-17Rs) were increased in neuropathic, inflammatory, and cancer pain models. Notably, IL-17/IL-17R antibodies also reportedly relieve or cure inflammatory- and pain-related diseases. However, existing studies have reported controversial results regarding IL-17/IL-17Rs as potential therapeutic targets in diverse animal models of chronic pain. In this review, we present a summary of published studies and discuss the evidence, from basic to clinical to research, regarding the role and mechanism of action between IL-17 and diverse kinds of chronic pain in animal models and clinical patients. Furthermore, we evaluated IL-17-based therapy as a potential therapeutic strategy for inflammatory- and pain-related disease. Importantly, we also discussed clinical trials of IL-17/IL-17R targeting monoclonal antibodies. Overall, we found that IL-17 is a potential therapeutic target for chronic pain from the perspective of neuroinflammation.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Inflammation, a section of the journal Frontiers in Immunology
Edited by: Eva Reali, University of Milano-Bicocca, Italy
These authors have contributed equally to this work and share first authorship
Reviewed by: Wuping Sun, Affiliated Nanshan Hospital of Shenzhen University Health Science Center, China; Guangyou Duan, Chongqing Medical University, China
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.999407